- To examine the extra cost of using higher-priced drugs as initial therapy for dermatophyte infections, because the many available effective drugs vary considerably in cost.
- Cost analysis from the purchaser's perspective, comparing two prototypical regimens to treat tinea pedis : one in which all patients initially receive a lower-priced drug and those with unresponsive infections receive a higher-priced drug at a follow-up office visit, and one in which all patients receive the higher-priced drug from the outset.
The reference drug was miconazole, an imidazole available without a prescription, for which reported overall efficacy rates are 70% to 100%.
Mots-clés Pascal : Mycose, Infection, Dermatophyte, Homme, Chimiothérapie, Traitement, Coût, Economie santé, Voie externe, Peau pathologie
Mots-clés Pascal anglais : Mycosis, Infection, Dermatophyte, Human, Chemotherapy, Treatment, Costs, Health economy, Topical administration, Skin disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0175978
Code Inist : 002B05D02B. Création : 09/06/1995.